Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ONCOSEC MEDICAL IncONCS · Entity 117092 | Director | January 02, 2019 | January 04, 2019 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director · Chief Executive Officer | August 07, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ONCOSEC MEDICAL Inc
Report date January 02, 2019 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-01-02 | Direct | 50,000 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 50,000 · Balance 50,000 F1: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021 pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021 pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.
Skye Bioscience, Inc.
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,419,823 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 1,090,000 · Balance 1,419,823 F1: Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 9,343 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,343 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arch Therapeutics, Inc.
Report date November 10, 2022 · Filed November 11, 2022
Section 16 reporting ended · disclosed 2021-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2032-11-10 | Direct | 250,000 |
Reported balance
After 2022-11-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-10 · Grant · Acquired 250,000 · Balance 250,000 F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 12 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 12 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2016 Filed Dec 16, 2016 17:25 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.60 | Not disclosed |
DisclosureSEC source: 0001493152-16-015977 · form4.xml · derivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-03-03 F1 · security: These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 25000 shares (previously granted on April 25, 2012), 12500 shares (previously granted on February 8, 2013), 100000 shares (previously granted on March 7, 2014), 25000 shares (previously granted on March 3, 2015), and 500000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 314583 shares of common stock with an exercise price of $1.29 per share. F7 · derivative.exercise_date: The stock options were scheduled to fully vest on March 3, 2018, the third anniversary of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:25 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerNon-qualified Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $16.10 | Not disclosed |
DisclosureSEC source: 0001493152-16-015977 · form4.xml · derivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2024-03-07 F5 · security: These stock options were granted as Non-qualified stock options. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 25000 shares (previously granted on April 25, 2012), 12500 shares (previously granted on February 8, 2013), 100000 shares (previously granted on March 7, 2014), 25000 shares (previously granted on March 3, 2015), and 500000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 314583 shares of common stock with an exercise price of $1.29 per share. F6 · derivative.exercise_date: The stock options were scheduled to fully vest on March 7, 2017, the third anniversary of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:25 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001493152-16-015977 · form4.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-02-08 F1 · security: These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 25000 shares (previously granted on April 25, 2012), 12500 shares (previously granted on February 8, 2013), 100000 shares (previously granted on March 7, 2014), 25000 shares (previously granted on March 3, 2015), and 500000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 314583 shares of common stock with an exercise price of $1.29 per share. F4 · derivative.exercise_date: The stock options were scheduled to fully vest on February 8, 2016, the third anniversary of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:25 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001493152-16-015977 · form4.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-04-25 F1 · security: These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 25000 shares (previously granted on April 25, 2012), 12500 shares (previously granted on February 8, 2013), 100000 shares (previously granted on March 7, 2014), 25000 shares (previously granted on March 3, 2015), and 500000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 314583 shares of common stock with an exercise price of $1.29 per share. F2 · derivative.exercise_date: The stock options were scheduled to fully vest on April 25, 2015, the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.